Opioid-sparing protocols reshape surgical analgesia spending
The global postoperative pain medication market was valued at USD 38.08 billion in 2025 and is projected to increase from USD 40.29 billion in 2026 to USD 66.92 billion by 2035, registering a CAGR of 5.80% during 2026–2035. Demand comes from hospitals, ambulatory surgery centers and pain services that treat patients after orthopedic, abdominal, cardiothoracic and obstetric procedures, first with injectable agents in the operating room and then with oral tablets at discharge. North America held the largest regional share, 41.0% in 2025, because branded long-acting local anesthetics and the first NaV1.8 inhibitor sell at high prices almost entirely there. Asia Pacific is the fastest-growing region at 7.1% a year, as Chinese regulators approve domestic liposomal and peripheral analgesics. The main commercial change is a U.S. payment rule that pays separately for qualifying non-opioid drugs in outpatient surgery, which lets premium products compete with generic opioids that cost a few cents per tablet.
Which surgical analgesics does the estimate count and leave out?
The estimate counts medicines given to prevent or treat pain after surgery, from intravenous opioids and acetaminophen in the recovery room to long-acting local anesthetics injected into the wound and oral tablets taken at home. Opioids, NSAIDs, acetaminophen, NaV1.8 inhibitors, local anesthetics and adjuncts such as gabapentinoids are valued at manufacturer selling prices.
Infusion pumps, cryoneurolysis systems, nerve stimulators and the general anesthetics used during the operation sit outside the estimate, although many of them are bought in the same protocol. Hospitals buy through group purchasing contracts and formulary committees, while discharge tablets reach patients through retail pharmacies.

Postoperative Pain Medication Market Insights
- The market is valued at USD 38.08 billion in 2025 and is projected to reach USD 66.92 billion by 2035, growing at a 5.80% CAGR as non-opioid protocols spread.
- North America led with 41.0% of 2025 value, because the United States pays the highest prices for branded depots and NaV1.8 tablets.
- Opioid Analgesics held 38.0% of 2025 value, as generic intravenous and oral opioids remain the default rescue option after surgery.
- The FDA approved Journavx, the first NaV1.8 pain signal inhibitor, on Jan. 30, 2025, opening a new oral non-opioid class for acute pain.
- Pacira settled its Exparel patent cases in April 2025, allowing volume-limited generic liposomal bupivacaine in the United States from early 2030.
Opioids still lead while non-opioid agents grow fastest
Why do opioids lead while non-opioid analgesics grow fastest?
Based on medication type, the market is categorized into opioid analgesics, non-opioid analgesics, local anesthetics and adjunctive medications. Opioid Analgesics led with 38.0% of 2025 value because intravenous morphine and hydromorphone remain standard rescue drugs, and U.S. pharmacies still dispensed 35.4 opioid prescriptions per 100 persons in 2024, against 46.8 in 2019, according to the CDC. Non-Opioid Analgesics grow fastest at 7.3% a year as new oral agents reach discharge regimens, with about 900,000 Journavx prescriptions filled in the first half of 2026, Vertex reported. That pace suggests prescribers now try a non-opioid first more often.
Why does oral dosing lead while regional delivery grows fastest?
Based on route of administration, the market is categorized into oral, intravenous, epidural and regional, intramuscular and transdermal delivery, with regional covering wound infiltration, nerve blocks and intrathecal dosing. Oral dosing led with 40.0% of 2025 value because most patients finish recovery at home, and FDA labeling says many surgical pain conditions need no more than a few days of immediate-release opioid. Epidural and Regional delivery grows fastest at 7.2% a year as long-acting blocks spread, with Pacira reporting 6% Exparel volume growth in 2025 and Hengrui winning Chinese approval for nerve-block use in 2025.
Why do orthopedic cases lead while obstetric surgery grows fastest?
Based on surgical procedure, the market is categorized into orthopedic, abdominal, cardiothoracic, gynecological and obstetric, neurosurgical and other procedures. Orthopedic Surgeries led with 31.0% of 2025 value because joint and spine surgery causes intense pain for several days, and CMS removed 285 mostly musculoskeletal procedures from its inpatient-only list for 2026, widening outpatient pathways like those already used for knee replacement, which rely on long-acting blocks. Gynecological and Obstetric Surgeries grow fastest at 6.9% a year as cesarean births rise, and the World Health Organization projects that 29% of births will be cesarean by 2030, up from 21%.
Why do hospitals lead while surgery centers grow fastest?
Based on end user, the market is categorized into hospitals and clinics, ambulatory surgery centers and pain management centers. Hospitals and Clinics led with 68.0% of 2025 value because inpatient and complex cases still happen there, and Vertex said in November 2025 that more than 750 hospitals had added Journavx to formularies, protocols or order sets. Ambulatory Surgery Centers grow fastest at 7.4% a year as procedures leave the hospital, and the number of Medicare-certified ambulatory surgery centers reached 6,436 in 2024, up 2.2%, according to MedPAC. Surgery centers therefore favor drugs that speed same-day discharge and avoid opioid side effects.
| Segment Group | Leading Sub-segment | Share, 2025 | Fastest-growing Sub-segment | CAGR, 2026–2035 |
|---|---|---|---|---|
| By Medication Type | Opioid Analgesics | 38.0% | Non-Opioid Analgesics | 7.3% |
| By Route of Administration | Oral | 40.0% | Epidural and Regional | 7.2% |
| By Surgical Procedure | Orthopedic Surgeries | 31.0% | Gynecological and Obstetric Surgeries | 6.9% |
| By End User | Hospitals and Clinics | 68.0% | Ambulatory Surgery Centers | 7.4% |
Branded non-opioids cost far more than generic tablets
Postoperative analgesic prices span four orders of magnitude, which shapes every formulary decision. Generic opioid and NSAID tablets cost U.S. pharmacies a few cents each, while a branded oral NaV1.8 inhibitor lists above USD 15 per tablet and a liposomal bupivacaine dose costs far more. Hospitals paid under bundled inpatient rates absorb the premium themselves, so they restrict branded agents to high-risk patients. In outpatient surgery, Medicare separate payments up to set limits move that calculation, which explains why branded suppliers concentrate their sales effort on surgery centers and hospital outpatient departments.
| Product or reference | Typical price or fee | Basis |
|---|---|---|
| Journavx (suzetrigine) 50 mg tablet | USD 15.50 per tablet, wholesale acquisition cost | Vertex Pharmaceuticals, January 2025 |
| Oxycodone and acetaminophen 5 mg and 325 mg tablet | USD 0.12 per tablet, average acquisition cost | CMS NADAC file, December 2025 |
| Ibuprofen 800 mg tablet | USD 0.06 per tablet, average acquisition cost | CMS NADAC file, December 2025 |
| Celecoxib 200 mg capsule | USD 0.09 per capsule, average acquisition cost | CMS NADAC file, December 2025 |
| Exparel (bupivacaine liposome) outpatient claim | Up to USD 2,443.20 separate Medicare payment | CMS Section 4135 product list, 2026 |
Request a Free Sample
Fill in your details and we'll send you a free sample report.
- Sample data tables & charts
- Research methodology
Surgery volume, NOPAIN payments and NaV1.8 drugs lift demand
Rising operation counts widen the treated population
Surgical volume sets the floor for demand, because almost every operation ends with some form of analgesia in recovery and many continue with tablets at home. A study in the WHO Bulletin estimated 312.9 million operations worldwide in 2012, up from 226.4 million in 2004, and called the volume large and growing. The same study found that very-low-expenditure countries performed only 6.3% of operations while holding 36.8% of the world population, so surgical access in poorer countries remains far below need. That gap means volume growth will come increasingly from middle-income health systems, while North America keeps the largest share of value because prices there are highest. Suppliers with low-cost injectables gain most from the volume, while branded agents gain from the price.
Medicare separate payments reward non-opioid choices in outpatient surgery
U.S. payment policy now pays hospitals and surgery centers to choose non-opioid drugs, which removes the main reason outpatient buyers avoided branded agents. CMS pays separately for qualifying non-opioid treatments in hospital outpatient departments and surgery centers from Jan. 1, 2025, through Dec. 31, 2027, with each payment capped at about 18% of the related procedure fee. For 2026, CMS listed five qualifying drugs and 11 devices, including On-Q elastomeric infusion pumps used for continuous nerve blocks. Journavx joined the list on Jan. 23, 2026, and Caldolor on March 11, 2026. Branded suppliers gain a reimbursed route into same-day surgery, while generic opioid makers lose part of the outpatient protocol.

Regulators restrict opioids for short postoperative courses
Regulators in the United States and the United Kingdom are narrowing how opioids may be used after surgery, which pushes prescribers toward multimodal regimens built on other drug classes. The MHRA removed the postoperative pain indication from prolonged-release morphine and oxycodone on March 12, 2025, citing persistent postoperative opioid use of 2% to 44% across European evidence. The FDA required new labeling for all opioid pain medicines on July 31, 2025, which says immediate-release opioids should be the first-line option if an opioid is needed. That guidance shrinks per-patient opioid volume for makers of opioid drugs and favors local anesthetics and NSAIDs.
The first NaV1.8 inhibitor creates a new oral class
A new drug class has entered acute pain treatment, giving surgeons an oral option that blocks pain signals in peripheral nerves without opioid effects in the brain. The FDA approved Journavx (suzetrigine) on Jan. 30, 2025, after two trials in pain following abdominoplasty and bunionectomy, with safety data from 874 participants and Breakthrough Therapy, Fast Track and Priority Review designations. Vertex said in August 2026 that about 260 million people in the United States had reimbursed access and that 23 state Medicaid programs covered the drug. Broad coverage turns a premium-priced tablet into a routine discharge choice, which lifts value per patient in the non-opioid segment.
Fixed-dose injectables, new NaV1.8 rivals and generic depots
Fixed-dose non-opioid injectables are replacing ad hoc mixes
Hospitals are shifting toward ready-made non-opioid injectables and kits to standardize multimodal protocols and reduce pharmacy compounding. Hikma launched Combogesic IV, a fixed combination of acetaminophen and ibuprofen developed by AFT Pharmaceuticals, in the United States in February 2024, which competes with separate vials of intravenous ibuprofen and acetaminophen. The FDA approved replacement 10 mL and 20 mL kit components for Heron's Zynrelef on April 17, 2025, a packaging supplement that keeps the kit format current. Zynrelef has qualified for separate Medicare outpatient payment since Jan. 1, 2026. Suppliers that package drugs for easy use gain formulary slots, while single-agent generic vials lose share in protocols.
Second-wave NaV1.8 and fast NSAID candidates near the market
Developers are moving toward faster-acting oral non-opioids to give surgeons more than one new tablet option, which creates more choice for discharge regimens after 2026. Latigo Biotherapeutics said in a release on July 29, 2026, that its NaV1.8 inhibitor LTG-001 met its primary endpoint after abdominoplasty in 343 participants, with 52.3% of high-dose patients opioid-free over 48 hours against 22.1% on placebo. The FDA accepted Viatris's application for fast-acting meloxicam in May 2026, backed by hernia and bunion surgery trials, with a goal date of Dec. 27, 2026. More rivals should cap tablet prices and widen hospital choice. In China, Haisco won NMPA approval for HSK21542, a peripheral kappa opioid agonist, for pain after abdominal surgery in May 2025.

Generic liposomal bupivacaine opens a volume-limited U.S. window
The first generic entry into long-acting bupivacaine creates an opening for injectable generic makers and lower-cost supply for surgery centers. Pacira settled its Exparel patent litigation with Fresenius Kabi, Jiangsu Hengrui and eVenus on April 7, 2025, licensing volume-limited generic sales from early 2030. The licensed share starts at a high-single-digit percentage of U.S. volume and reaches the low thirties in 2033, while the last listed patent runs to July 2, 2044. The FDA had already approved Hengrui's bupivacaine liposome in July 2024. Hospitals that limited Exparel on cost can widen use once the generic share grows.
Underserved surgical markets offer room for low-cost non-opioids
Middle-income health systems are an opening for suppliers of low-cost injectable non-opioids, because opioid access there is limited and surgery volume is rising. High-income countries consume about 92% of available opioids while low- and middle-income countries receive about 8%, according to an IASP fact sheet citing the International Narcotics Control Board. Cumberland Pharmaceuticals said on Oct. 1, 2025, that its injectable ibuprofen was approved in Mexico, where PiSA Farmaceutica plans an 800 mg vial launch. Health Canada accepted Vertex's submission for suzetrigine in the second quarter of 2026. Licensing partners with local hospital sales teams can reach these buyers faster than originators alone.
Payment cliffs, price gaps and opioid liability weigh
Temporary outpatient payments create a 2027 cliff
The Medicare separate payments described above are temporary and end on Dec. 31, 2027, unless Congress or CMS extends them. Branded suppliers such as Pacira, Heron and Vertex are most exposed, because surgery centers would again absorb the full drug cost inside the procedure fee from 2028. Centers that built protocols around reimbursed drugs may then revert to generic bupivacaine and opioids. Buyers that built budgets around reimbursed drugs should model both outcomes before their supply contracts renew.
Bundled inpatient payment keeps branded agents rationed
Inpatient stays are paid as a bundle, so a hospital pays the full premium for a branded analgesic with no separate payment. Generic oxycodone and acetaminophen tablets cost U.S. pharmacies about USD 0.12 each in December 2025, according to CMS acquisition cost data, against a USD 15.50 list price for one Journavx tablet. Pharmacy and therapeutics committees therefore restrict branded drugs to high-risk patients, which limits volume for originators in inpatient care.
Opioid harm data raise liability and protocol pressure
New label data make the risks of opioid exposure more visible to surgeons and hospital risk managers. The FDA's July 2025 labeling changes added postmarketing findings that about 22% of patients on long-term opioids newly met misuse criteria over 12 months, with five-year overdose incidence of about 1.5% to 4%. Generic opioid makers such as Hikma and Fresenius Kabi are most exposed, because hospitals that tighten discharge quantities buy fewer tablets per case.
Group purchasing discounts compress branded net prices
Large hospital buying groups are extracting deeper discounts on branded analgesics as competition rises. Pacira said on Jan. 8, 2026, that a new group purchasing organization partnership drove discounting and a shift in vial mix during 2025, even as Exparel volume grew. Branded depot suppliers face the strongest pressure, because volume gains no longer translate fully into value, and the effect will deepen once generic liposomal bupivacaine arrives in 2030.
North America leads on price, Asia Pacific grows fastest
| Region | Value, 2025 (USD billion) | Share, 2025 | CAGR, 2026–2035 |
|---|---|---|---|
| North America | 15.61 | 41.0% | 5.4% |
| Europe | 9.52 | 25.0% | 4.9% |
| Asia Pacific | 8.76 | 23.0% | 7.1% |
| Latin America | 2.28 | 6.0% | 6.3% |
| Middle East & Africa | 1.90 | 5.0% | 6.4% |
North America leads on branded prices and outpatient payment
North America held 41.0% of 2025 value and grows at 5.4% a year, because the United States pays the highest prices for branded depots and NaV1.8 tablets and now reimburses them separately in outpatient surgery. Medicare spending on surgery center services reached about USD 7.5 billion in 2024, up 13.0% from 2023, MedPAC reported, which shows how fast the same-day setting is growing. Canada adds a second market for new oral agents once its suzetrigine review ends.
Europe grows slowest under opioid curbs and tight budgets
Europe held 25.0% of 2025 value and grows at 4.9% a year, the slowest rate, because national tenders keep analgesic prices low and the U.K. restriction on prolonged-release opioids noted above trims opioid volume. The same MHRA review found that postoperative pain usually lasts five to seven days and put opioid-induced ventilatory impairment at 0.4% to 41% of patients, which favors short immediate-release courses over long-acting tablets. This review found no NaV1.8 inhibitor approved in the European Union by November 2026, so new-class revenue there remains an evidence gap.

Asia Pacific grows fastest on Chinese approvals and surgery access
Asia Pacific held 23.0% of 2025 value and grows fastest at 7.1% a year, because Chinese regulators are approving domestic long-acting and peripheral analgesics and surgical capacity keeps expanding. Hengrui's Aihengping, a generic liposomal bupivacaine, gained NMPA approval for adductor canal and popliteal sciatic nerve blocks in 2025, adding to its earlier infiltration use. Haisco's May 2025 approval of HSK21542 for pain after abdominal surgery, noted in the trends, gives Chinese hospitals a second domestic non-opioid option alongside Hengrui's depot.
Latin America leans on high cesarean rates and licensed injectables
Latin America held 6.0% of 2025 value and grows at 6.3% a year, because obstetric surgery is unusually common and multinational injectables reach hospitals through local licensees. Cesarean births already account for 43% of all births in Latin America and the Caribbean and could reach 54% by 2030, WHO research shows. The Mexican injectable ibuprofen approval noted above shows how partners such as PiSA carry new non-opioid products into public and private hospitals.
Middle East & Africa splits between Gulf hospitals and thin access
Middle East & Africa held 5.0% of 2025 value and grows at 6.4% a year, because Gulf hospitals buy branded injectables while much of Africa lacks basic surgical analgesia. WHO research projects cesarean rates of 50% in Western Asia and 48% in Northern Africa by 2030, against only 5% in sub-Saharan Africa. Public data on morphine and other analgesic use in the Gulf states are thin, so this share carries a wide error range.

Approvals, a patent deal and filings marked 2025 and 2026
| Development | Status and market relevance |
|---|---|
| In January 2025, the FDA approved Vertex's Journavx (suzetrigine) 50 mg tablets for moderate-to-severe acute pain in adults. | Approval completed; first NaV1.8 inhibitor, now prescribed in hospital and retail settings across the United States. |
| In April 2025, Pacira settled its Exparel patent litigation with Fresenius Kabi, Jiangsu Hengrui and eVenus. | Completed settlement; licenses volume-limited U.S. generic liposomal bupivacaine from early 2030 and unlimited volume no earlier than 2039. |
| In October 2025, Cumberland Pharmaceuticals announced approval of its injectable ibuprofen in Mexico through partner PiSA Farmaceutica. | Regulatory approval; PiSA plans the 800 mg vial launch, expanding non-opioid hospital options in Latin America. |
| In May 2026, the FDA accepted Viatris's new drug application for fast-acting meloxicam for moderate-to-severe acute pain. | Under review; goal date Dec. 27, 2026, which could add a second new oral non-opioid option in 2027. |
| In July 2026, Latigo Biotherapeutics reported that its NaV1.8 inhibitor LTG-001 met its primary endpoint after abdominoplasty. | Testing milestone; positive dose-ranging results point to a second NaV1.8 competitor, with no approval filing yet announced. |
Sodium channel blockade and depot delivery cut opioid use
- Selective NaV1.8 inhibition blocks pain signals in peripheral sensory nerves, which relieves acute pain without opioid reward or respiratory effects in the brain.
- Multivesicular liposome depots release bupivacaine slowly from one injection, which extends wound and nerve-block analgesia beyond plain bupivacaine.
- Polymer-based extended-release solutions combine bupivacaine with meloxicam in a viscous polymer solution, which keeps both drugs in the wound and dampens local inflammation.
- Peripherally restricted opioid agonists act on kappa receptors outside the brain, which aims to relieve visceral pain with less sedation and lower abuse potential.
Need a Custom Version of This Report?
Tailor the scope, geography, or segments to your exact requirements.
- Custom geography or segment scope
- Direct access to our analyst team
Branded depots and NaV1.8 drugs compete with generic opioids
Competition turns on clinical data, protocol placement and reimbursement rather than on list price alone. Pacira sells Exparel liposomal bupivacaine and leads the long-acting local anesthetic class, while Heron sells Zynrelef for wound infiltration. Vertex owns the only approved NaV1.8 tablet and is building hospital and payer access. Pfizer, Fresenius Kabi and Hikma supply the generic injectable opioids, local anesthetics and NSAIDs that still fill most recovery room orders, and Hikma also markets Combogesic IV from AFT Pharmaceuticals. Cumberland Pharmaceuticals sells Caldolor injectable ibuprofen to hospitals and licenses it abroad. In China, Jiangsu Hengrui and Haisco are building domestic depot and peripheral analgesic franchises. Suppliers of postoperative pain medication that combine a branded product with hospital contracting strength hold the best position, while single-product companies depend on one payment rule. The eleven companies profiled below cover branded, generic and Chinese supply.
How is the supply side organized and where do margins sit?
Postoperative pain medication supply splits into two tiers that rarely compete on the same terms. Generic injectable houses such as Pfizer's Hospira unit, Fresenius Kabi and Hikma sell morphine, hydromorphone, ketorolac, bupivacaine and acetaminophen under hospital tenders with thin margins and limited differentiation. A small group of branded specialists, led by Pacira, Heron and Vertex, sells patented depots and oral agents with high gross margins but needs large hospital sales forces and payer access. Entry barriers sit in liposomal manufacturing, sterile capacity and clinical data, and Chinese firms such as Hengrui and Haisco are building both tiers at home.
Companies profiled and their roles in this market
| Company | Type | Role in the market |
|---|---|---|
| Pacira BioSciences, Inc. | Branded specialist | Sells Exparel liposomal bupivacaine for wound infiltration and nerve blocks |
| Vertex Pharmaceuticals Incorporated | Branded originator | Sells Journavx, the first approved NaV1.8 inhibitor for acute pain |
| Pfizer Inc. | Generic injectables supplier | Hospira unit sells injectable morphine, hydromorphone, bupivacaine and ketorolac |
| Fresenius Kabi AG (Fresenius SE) | Generic injectables supplier | Sells injectable opioids and local anesthetics; licensed for generic liposomal bupivacaine |
| Hikma Pharmaceuticals PLC | Generic injectables supplier | Sells injectable opioids and markets Combogesic IV in the United States |
| Heron Therapeutics, Inc. | Branded specialist | Sells Zynrelef extended-release bupivacaine and meloxicam for surgical wounds |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Chinese originator and generic maker | Sells liposomal bupivacaine in China and holds U.S. approval |
| Haisco Pharmaceutical Group Co., Ltd. | Chinese originator | Markets HSK21542 for pain after abdominal surgery in China |
| Cumberland Pharmaceuticals Inc. | Specialty pharmaceutical company | Sells Caldolor injectable ibuprofen in hospitals and licenses it abroad |
| AFT Pharmaceuticals Limited | Specialty pharmaceutical company | Developed Maxigesic IV, sold in the United States as Combogesic IV |
| Viatris Inc. | Generic and specialty supplier | Sells generic oral analgesics; fast-acting meloxicam under FDA review |
Outpatient reimbursement decides who wins premium share
Credence Research's view is that outpatient reimbursement, more than clinical evidence, will decide how fast premium postoperative pain medication gains share before 2030. The clinical case for opioid-sparing care is settled in guidelines, but hospitals still buy on budget, and the temporary Medicare payments are the main reason surgery centers now pay for branded agents. Suppliers should build data on discharge outcomes and readmissions that will justify use if payments lapse. Hospital buyers should prepare for generic liposomal bupivacaine in 2030 and for a second NaV1.8 entrant that could pressure tablet prices.
Earlier estimate rolled forward and tested on surgery volume
The report uses 2025 as the base year and forecasts to 2035. The earlier Credence Research estimate for 2022 was rolled forward three years at its own growth rate and tested against an estimate of global operation counts multiplied by typical analgesic spend per operation in high- and low-spending health systems. Segment and regional shares are Credence Research estimates based on surgical volume, drug prices, reimbursement rules and product approvals. Sources include the FDA, CMS, MedPAC, the MHRA, WHO, the CDC, company releases and filings. No interviews or surveys were conducted for this update of the estimate.
Non-opioid adoption and generic depots set growth to 2035
Postoperative pain medication spending to 2035 depends on reimbursement and on how quickly non-opioid tablets replace opioids at discharge. The base case assumes Medicare keeps some form of separate payment after 2027, that NaV1.8 drugs keep gaining hospital and payer access, and that generic liposomal bupivacaine from 2030 widens depot use at lower prices. Demand in the base case grows at 5.80% a year over 2026–2035, led by non-opioid agents and regional blocks. Opioids should keep a large but shrinking share as rescue drugs, while China and other middle-income markets add volume as surgical access improves and domestic companies launch long-acting products.
Payment policy and generic entry set the range of outcomes
The spread of outcomes depends mainly on whether Medicare extends separate non-opioid payments beyond 2027 and on how quickly NaV1.8 tablets displace opioids at discharge. Generic liposomal bupivacaine from 2030 lowers prices but widens use, so its net effect on value is modest. A downside follows if payments lapse and hospitals revert to generic opioids, while the upside needs a second NaV1.8 approval and wider coverage outside the United States.
| Scenario | CAGR, 2026–2035 | Value, 2035 | What has to hold |
|---|---|---|---|
| Downside | 4.4% | USD 59.36 billion | Separate payments lapse after 2027 and branded agents return to restricted use |
| Base | 5.80% | USD 66.92 billion | Payments are extended in part and NaV1.8 tablets keep gaining discharge share |
| Upside | 7.0% | USD 74.07 billion | A second NaV1.8 drug launches and Europe and China approve new non-opioid classes |
Frequently Asked Questions
How big is the postoperative pain medication market?
Is this the same as the post-operative pain management market?
Which medication type holds the largest share?
Which region leads the market?
How is the U.S. post-operative pain market changing?
Where do intrathecal and epidural drugs fit in the estimate?
Is morphine still used after surgery in the Gulf states?
Who are the main postoperative pain therapeutics companies?
Table of Content
Chapter 1 Market Segmentation
- 1.1 Segmentation Framework
- 1.1.1 Product and Service Classification
- 1.1.2 Application and End-Use Classification
- 1.1.3 Technology and Solution Classification
- 1.1.4 Customer and Distribution Channel Classification
- 1.1.5 Geographic Segmentation
- 1.1.6 Market Segment Definitions and Boundaries
- 1.2 By Medication Type
- 1.2.1 Opioid Analgesics
- 1.2.2 Non-Opioid Analgesics
- 1.2.3 Local Anesthetics
- 1.2.4 Adjunctive Medications
- 1.3 By Route of Administration
- 1.3.1 Oral
- 1.3.2 Intravenous
- 1.3.3 Epidural and Regional
- 1.3.4 Intramuscular
- 1.3.5 Transdermal
- 1.4 By Surgical Procedure
- 1.4.1 Orthopedic Surgeries
- 1.4.2 Abdominal Surgeries
- 1.4.3 Cardiothoracic Surgeries
- 1.4.4 Gynecological and Obstetric Surgeries
- 1.4.5 Neurosurgical Procedures
- 1.4.6 Others
- 1.5 By End User
- 1.5.1 Hospitals and Clinics
- 1.5.2 Ambulatory Surgery Centers
- 1.5.3 Pain Management Centers
Chapter 2 Introduction
- 2.1 Report Objectives and Scope
- 2.2 Product Definition and Industry Terminology
- 2.3 Market Inclusions and Exclusions
- 2.4 Research Process
- 2.4.1 Primary Research and Expert Interviews
- 2.4.2 Secondary Research and Source Review
- 2.4.3 Top-Down and Bottom-Up Estimation
- 2.4.4 Data Triangulation and Verification
- 2.5 Market Size Measurement Basis
- 2.5.1 2025: USD 38.08 billion → 2035: USD 66.92 billion
- 2.6 Historical and Forecast Reference Periods
- 2.6.1 Historical Period: 2018-2025
- 2.6.2 Base Year: 2025
- 2.6.3 Forecast Period: 2025-2035
- 2.7 Research Assumptions and Limitations
Chapter 3 Executive Summary
- 3.1 Market Snapshot and Key Findings
- 3.2 Base-Year Market Size, 2025
- 3.3 Forecast Market Size, 2035
- 3.4 Revenue and Volume Growth Outlook
- 3.5 Key Demand and Supply Indicators
- 3.6 Leading Market Segments
- 3.7 Fastest-Growing Market Opportunities
- 3.8 Regional Performance Highlights
- 3.9 Technology and Industry Transformation
- 3.10 Competitive Landscape Summary
- 3.11 Analyst View and Strategic Implications
Chapter 4 Global Postoperative Pain Medication Market Trends and Developments
- 4.1 Historical Industry Development, 2018-2025
- 4.2 Recent Market Trends and Developments
- 4.3 Demand and Customer Behavior Trends
- 4.4 Technology and Product Innovation
- 4.5 Artificial Intelligence, Automation and Digitalization
- 4.6 Local Manufacturing and Supply Chain Realignment
- 4.7 Industry Partnerships, Mergers and Acquisitions
- 4.8 Sustainability and Circular Economy Developments
- 4.9 Government and Private Sector Investment Trends
- 4.10 Emerging Business Models and Commercialization
- 4.11 Industry Developments and Announcements
Chapter 5 Global Postoperative Pain Medication Market Production, Supply and Demand Analysis
- 5.1 Demand Trend and Consumption Analysis, 2018-2025
- 5.2 Demand Forecast, 2025-2035
- 5.3 Production and Output Trend, 2018-2025
- 5.4 Production and Output Forecast, 2025-2035
- 5.5 Installed Capacity and Capacity Utilization
- 5.6 Company-Wise Production Plants and Statistics
- 5.6.1 Installed Production Capacity
- 5.6.2 Actual Production
- 5.6.3 Planned Capacity and Expansion Targets
- 5.7 Supply Chain Structure and Procurement Trends
- 5.8 Supply-Demand Gap and Bottlenecks
- 5.9 Import Dependence and Sourcing Structure
- 5.10 Contract Manufacturing and Outsourcing
- 5.11 Regional Supply and Demand Concentration
Chapter 6 Global Postoperative Pain Medication Market Pricing Analysis
- 6.1 Pricing Structure and Measurement
- 6.2 Historical Pricing Trends, 2018-2025
- 6.3 Pricing Outlook, 2025-2035
- 6.4 Average Selling Price and Unit Economics
- 6.5 Pricing by Product and Market Segment
- 6.6 Geographic Pricing Differences
- 6.7 Key Input, Energy, Labor and Logistics Costs
- 6.8 Contract Pricing and Purchasing Models
- 6.9 Pricing Sensitivity and Competitive Positioning
- 6.10 Price, Margin and Profitability Implications
Chapter 7 Global Postoperative Pain Medication Market Dynamics
- 7.1 Market Growth Drivers
- 7.1.1 Demand-Side Drivers
- 7.1.2 Technology and Innovation Drivers
- 7.1.3 Infrastructure and Investment Drivers
- 7.1.4 Regulatory and Policy Drivers
- 7.2 Market Restraints
- 7.2.1 Cost and Affordability Constraints
- 7.2.2 Technology and Adoption Barriers
- 7.2.3 Supply Chain and Operational Constraints
- 7.3 Market Challenges
- 7.3.1 Competitive Pressure and Margin Erosion
- 7.3.2 Skills, Infrastructure and Implementation Gaps
- 7.4 Emerging Market Opportunities
- 7.5 Market Dynamics Impact and Time-Horizon Assessment
Chapter 8 Global Postoperative Pain Medication Value Chain Analysis
- 8.1 Industry Value Chain Overview
- 8.2 Upstream Suppliers and Critical Inputs
- 8.3 Technology and Component Providers
- 8.4 Manufacturing or Service Delivery
- 8.5 Distribution, Channel Partners and Integrators
- 8.6 Downstream Applications and End Users
- 8.7 Value Addition and Profit Pools
- 8.8 Vertical Integration and Outsourcing
- 8.9 Supplier Concentration and Risk
- 8.10 Supply Chain Localization and Resilience
Chapter 9 Global Postoperative Pain Medication Market Regulations and Policies
- 9.1 Relevant Laws, Standards and Compliance Frameworks
- 9.2 Product, Service, Safety and Quality Requirements
- 9.3 Government Policies, Incentives and Subsidies
- 9.4 Imports, Exports and Trade Barriers
- 9.5 Public Procurement and Local Content Requirements
- 9.6 Environmental and Sustainability Compliance
- 9.7 Upcoming Policy Changes and Market Implications
Chapter 10 Global Postoperative Pain Medication Market Hotspots and Opportunities
- 10.1 Market Opportunity Mapping and Growth Hotspots
- 10.2 High-Growth Applications and Customer Groups
- 10.3 Underserved Markets and White-Space Opportunities
- 10.4 Emerging Technology and Product Opportunities
- 10.5 New Capacity and Investment Hotspots
- 10.6 Market Entry and Expansion Opportunities
- 10.7 Distribution and Partnership Opportunities
- 10.8 Near-Term and Long-Term Commercial Potential
- 10.9 Opportunity Attractiveness and Execution Risks
Chapter 11 Global Postoperative Pain Medication Market Outlook, 2025-2035
- 11.1 Market Size and Analysis
- 11.1.1 Revenue (Market Measurement: 2025: USD 38.08 billion → 2035: USD 66.92 billion)
- 11.1.2 Market Volume and Quantity Sold
- 11.1.3 Historical Market Size, 2018-2025
- 11.1.4 Base-Year Market Size, 2025
- 11.2 Market Forecast, 2025-2035
- 11.2.1 Revenue Forecast to 2035
- 11.2.2 Volume Forecast to 2035
- 11.2.3 CAGR and Year-on-Year Growth
- 11.2.4 Incremental Revenue Opportunity
- 11.3 Forecast Assumptions and Scenario Analysis
- 11.3.1 Base-Case Forecast
- 11.3.2 Optimistic and Conservative Scenarios
- 11.3.3 Technology, Pricing and Policy Sensitivities
- 11.4 Market Attractiveness and Growth Outlook
Chapter 12 Global Postoperative Pain Medication Market Segmentation and Outlook
- 12.1 Segmentation Summary and Market Shares, 2025
- 12.2 Largest and Fastest-Growing Segments
- 12.3 By Medication Type - Market Size and Forecast, 2025-2035
- 12.3.1 Segment Definition and Scope
- 12.3.2 Historical Market Size, 2018-2025
- 12.3.3 Revenue Forecast, 2025-2035
- 12.3.4 Volume Forecast, 2025-2035
- 12.3.5 Base-Year Market Share, 2025
- 12.3.6 Segment CAGR and Growth Drivers
- 12.3.7 Subsegment Market Size and Forecast
- 12.3.7.1 Opioid Analgesics
- 12.3.7.2 Non-Opioid Analgesics
- 12.3.7.3 Local Anesthetics
- 12.3.7.4 Adjunctive Medications
- 12.3.8 Subsegment Pricing and Adoption Trends
- 12.3.9 Leading Suppliers and Competition
- 12.3.10 Regional Demand and Opportunities
- 12.4 By Route of Administration - Market Size and Forecast, 2025-2035
- 12.4.1 Segment Definition and Scope
- 12.4.2 Historical Market Size, 2018-2025
- 12.4.3 Revenue Forecast, 2025-2035
- 12.4.4 Volume Forecast, 2025-2035
- 12.4.5 Base-Year Market Share, 2025
- 12.4.6 Segment CAGR and Growth Drivers
- 12.4.7 Subsegment Market Size and Forecast
- 12.4.7.1 Oral
- 12.4.7.2 Intravenous
- 12.4.7.3 Epidural and Regional
- 12.4.7.4 Intramuscular
- 12.4.7.5 Transdermal
- 12.4.8 Subsegment Pricing and Adoption Trends
- 12.4.9 Leading Suppliers and Competition
- 12.4.10 Regional Demand and Opportunities
- 12.5 By Surgical Procedure - Market Size and Forecast, 2025-2035
- 12.5.1 Segment Definition and Scope
- 12.5.2 Historical Market Size, 2018-2025
- 12.5.3 Revenue Forecast, 2025-2035
- 12.5.4 Volume Forecast, 2025-2035
- 12.5.5 Base-Year Market Share, 2025
- 12.5.6 Segment CAGR and Growth Drivers
- 12.5.7 Subsegment Market Size and Forecast
- 12.5.7.1 Orthopedic Surgeries
- 12.5.7.2 Abdominal Surgeries
- 12.5.7.3 Cardiothoracic Surgeries
- 12.5.7.4 Gynecological and Obstetric Surgeries
- 12.5.7.5 Neurosurgical Procedures
- 12.5.7.6 Others
- 12.5.8 Subsegment Pricing and Adoption Trends
- 12.5.9 Leading Suppliers and Competition
- 12.5.10 Regional Demand and Opportunities
- 12.6 By End User - Market Size and Forecast, 2025-2035
- 12.6.1 Segment Definition and Scope
- 12.6.2 Historical Market Size, 2018-2025
- 12.6.3 Revenue Forecast, 2025-2035
- 12.6.4 Volume Forecast, 2025-2035
- 12.6.5 Base-Year Market Share, 2025
- 12.6.6 Segment CAGR and Growth Drivers
- 12.6.7 Subsegment Market Size and Forecast
- 12.6.7.1 Hospitals and Clinics
- 12.6.7.2 Ambulatory Surgery Centers
- 12.6.7.3 Pain Management Centers
- 12.6.8 Subsegment Pricing and Adoption Trends
- 12.6.9 Leading Suppliers and Competition
- 12.6.10 Regional Demand and Opportunities
- 12.7 Segment Growth Comparison
- 12.8 Segment Attractiveness and Priority Matrix
Chapter 13 Global Postoperative Pain Medication End-Use and Application Market Outlook
- 13.1 End-Use Industry and Customer Demand Structure
- 13.2 Leading Applications and Customer Groups
- 13.3 End-Use Market Size, Share and Forecast
- 13.4 Major End-Use Industry Deep Dives
- 13.4.1 Customer Requirements and Use Cases
- 13.4.2 Demand and Replacement Cycles
- 13.4.3 Technical and Regulatory Considerations
- 13.4.4 Purchasing and Procurement Models
- 13.4.5 Leading Vendors and Distribution Channels
- 13.4.6 Forecast and Commercial Opportunities
- 13.5 Emerging Applications and Cross-Segment Demand
- 13.6 End-Use Industry Investment Priorities
Chapter 14 Global Postoperative Pain Medication Geographic Market Outlook, 2025-2035
- 14.1 Regional Market Size and Share, 2025
- 14.2 Regional Market Forecast, 2025-2035
- 14.3 Regional Pricing, Production and Demand Differences
- 14.4 North America
- 14.4.1 United States
- 14.4.2 Canada
- 14.4.3 Mexico
- 14.5 Europe
- 14.5.1 Germany
- 14.5.2 France
- 14.5.3 Italy
- 14.5.4 United Kingdom
- 14.5.5 Spain
- 14.5.6 Poland
- 14.5.7 Russia
- 14.5.8 Netherlands
- 14.5.9 Belgium
- 14.5.10 Sweden
- 14.5.11 Denmark
- 14.5.12 Norway
- 14.5.13 Rest of Europe
- 14.6 Asia Pacific
- 14.6.1 China
- 14.6.2 India
- 14.6.3 Japan
- 14.6.4 South Korea
- 14.6.5 Thailand
- 14.6.6 Indonesia
- 14.6.7 Vietnam
- 14.6.8 Malaysia
- 14.6.9 Australia
- 14.6.10 Rest of Asia Pacific
- 14.7 Latin America
- 14.7.1 Brazil
- 14.7.2 Argentina
- 14.7.3 Colombia
- 14.7.4 Chile
- 14.7.5 Rest of Latin America
- 14.8 Middle East
- 14.8.1 Saudi Arabia
- 14.8.2 United Arab Emirates
- 14.8.3 Turkey
- 14.8.4 Israel
- 14.8.5 Iran
- 14.8.6 Rest of the Middle East
- 14.9 Africa
- 14.9.1 South Africa
- 14.9.2 Egypt
- 14.9.3 Nigeria
- 14.9.4 Morocco
- 14.9.5 Rest of Africa
- 14.10 Regional Investment, Policy and Supply Chain Differences
- 14.11 Regional Competitive Landscape
- 14.12 Geographic Growth Hotspots
Chapter 15 Global Postoperative Pain Medication Technology, Innovation and Sustainability Outlook
- 15.1 Technology Landscape and Maturity
- 15.2 Product, Process and Service Innovation
- 15.3 AI, Automation and Digital Tools in the Industry
- 15.4 Technology Adoption and Performance Benchmarking
- 15.5 Innovation Pipeline and R&D Investment
- 15.6 Patent and Intellectual Property Trends
- 15.7 Energy Efficiency and Resource Management
- 15.8 Sustainability, Recycling and Circularity
- 15.9 Technology Roadmap, 2025-2035
- 15.10 Risks of Obsolescence and Technology Substitution
Chapter 16 Global Postoperative Pain Medication Market Key Strategic Imperatives
- 16.1 Growth and Market Entry Priorities
- 16.2 High-Return Products and Segments
- 16.3 Pricing, Profitability and Cost Optimization
- 16.4 Technology Investment and Product Differentiation
- 16.5 Supply Chain Localization and Resilience
- 16.6 Distribution and Customer Acquisition
- 16.7 Partnership, Acquisition and Capacity Strategy
- 16.8 Regional Expansion Priorities
- 16.9 Short-, Medium- and Long-Term Actions
Chapter 17 Competition Outlook
- 17.1 Industry Competition Characteristics
- 17.2 Market Structure and Concentration
- 17.3 Market Share and Competitive Positioning, 2025
- 17.4 Company-Wise Revenue and Product Benchmarking
- 17.5 Production and Service Capacity Benchmarking
- 17.6 Technology, Pricing and Differentiation
- 17.7 Regional Footprint and Distribution Strength
- 17.8 Mergers, Acquisitions and Strategic Alliances
- 17.9 New Entrants and Competitive Threats
- 17.10 Porter's Five Forces and Industry Attractiveness
- 17.11 Competitive Outlook, 2025-2035
Chapter 18 Company Profiles
- 18.1 Company Coverage and Selection Criteria
- 18.2 Pacira BioSciences, Inc.
- 18.2.1 Business Description
- 18.2.2 Company Ownership and Geographic Presence
- 18.2.3 Product and Service Portfolio
- 18.2.4 Manufacturing and Operating Footprint
- 18.2.5 Production Capacity and Expansion Plans
- 18.2.6 Financial Performance and Investment
- 18.2.7 Market Share and Competitive Position
- 18.2.8 Technology and Innovation Capabilities
- 18.2.9 Strategic Alliances or Partnerships
- 18.2.10 Recent Developments
- 18.2.11 Growth Strategy and Outlook
- 18.3 Vertex Pharmaceuticals Incorporated
- 18.4 Pfizer Inc.
- 18.5 Fresenius Kabi AG (Fresenius SE)
- 18.6 Hikma Pharmaceuticals PLC
- 18.7 Heron Therapeutics, Inc.
- 18.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- 18.9 Haisco Pharmaceutical Group Co., Ltd.
- 18.10 Cumberland Pharmaceuticals Inc.
- 18.11 AFT Pharmaceuticals Limited
- 18.12 Viatris Inc.
- 18.13 Other Relevant Market Participants
Note: Every listed company is profiled on the structure shown under the first company. The company list is preliminary and may change based on research findings, market developments, data availability and client requirements.
Chapter 19 Disclaimer
- 19.1 Research and Forecast Disclaimer
- 19.2 Data Source and Estimation Limitations
Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.

